Trial · NCT04700176
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (Cohort A) | Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A) | 1 | Participants | ||
| Objective Response Rate (Cohort A) | Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B) | 0 | Participants | ||
| Incidence of Adverse Events | Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A) | 1 | Participants | ||
| Incidence of Adverse Events | Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B) | 0 | Participants | ||
| Rate of Stringent Complete Response | Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A) | 0 | Participants | ||
| Rate of Stringent Complete Response | Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B) | 0 | Participants | ||
| Incidence of Treatment-Emergent Adverse Events | Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A) | 1 | Participants | ||
| Incidence of Treatment-Emergent Adverse Events | Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B) | 0 | Participants | ||
| Rate of Minimal Residual Disease Evaluation | Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A) | 0 | Participants | ||
| Rate of Minimal Residual Disease Evaluation | Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B) | 0 | Participants | ||
| Time on Study (TOS) | Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A) | 8 | Months | ||
| Duration of Response (DOR) | Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A) | 8 | Months | ||
| Time To Progression (TTP) | Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A) | 8 | Months | ||
| Progression-Free Survival (PFS) | Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A) | 8 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04700176/results